Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma

Kim, Hye Min; Heo, Chan Mi; Oh, Jong Sik; Chung, Hwe Hoon; Lee, Eun Mi; Park, Juhee; Lee, Se‐Hoon; Lee, Kwang Hyuck; Lee, Jong Kyun; Cho, Yoon‐Kyoung; Park, Joo Kyung

doi:10.1016/j.tranon.2021.101321

Cited by 8 publications

(4 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…18 In addition, longitudinal monitoring of changes in CTCs after chemotherapy can provide insight into treatment outcomes in patients with PDCA. 19 A feasible strategy for improving the prognosis of pancreatic cancer was a better understanding of the pancreatic cancer metastasis process, and according to the prognosis of pancreatic cancer and metastasis biomarkers, cancer cells for the treatment of patients 20 with layers usually lose some characteristics of epithelial cells and gain a more mesenchymal phenotype, which was known as "epithelial-mesenchymal transition." 21 Epithelial-mesenchymal transformation increased mobility and invasiveness and was thought to contribute to metastasis.…”

Section: Discussionmentioning

confidence: 99%

Identification and gene expression analysis of circulating tumor cells with high expression of KRAS in pancreatic cancer

Zheng,

Chen,

Lin

et al. 2023

AIP Advances

View full text Add to dashboard Cite

This study aims to establish a highly sensitive and specific method for single cell screening and identification of KRAS+/epithelial cell adhesion molecules (EpCAMs)/vimentin+/pancreatic cancer circulating tumor cells (CTCs) and to explore the clinical implications in the diagnosis of pancreatic cancer. A single cell separation and identification system for pancreatic cancer CTCs was constructed based on the preparation of KRAS immunolipid magnetic spheres. The function of the system was evaluated, the physical parameters of the immunoliposomes (IMLs) were characterized, and the isolation effect of the IMLs on CTCs was studied and compared with EpCAM and vimentin phenotypic CTCs. CTCs in the peripheral blood of 50 patients with pancreatic cancer confirmed by preoperative CT diagnosis and postoperative pathology were isolated and identified. The isolated CTCs were stained with CK immune antibody, observed, and identified, the number of CTCs was counted, and the relationship between the CTC count and the clinical malignant grade markers and grade indicators was examined. The consistency of the KRAS mutation rate between CTCs and tissues was analyzed and compared. It was found that the circulating tumor cell sorting system with a high expression of KRAS-ML could effectively enrich the circulating tumor cells with a positive expression of KRAS in pancreatic cancer. The pancreatic cancer CTC sorting and single-cell gene detection system can be used as a new detection technology of peripheral blood CTCs in patients with pancreatic cancer. As a minimally invasive liquid biopsy method, this technology has significant clinical practice implications for pancreatic cancer detection and effectiveness assessment.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification and gene expression analysis of circulating tumor cells with high expression of KRAS in pancreatic cancer

Zheng,

Chen,

Lin

et al. 2023

AIP Advances

View full text Add to dashboard Cite

show abstract

“…Most studies have found that a decrease in CTC counts signifies a favourable treatment response [ 73 , 95 , 96 ]. However, some research suggests that there may not be a significant difference in CTC counts between blood samples collected before and after chemotherapy, possibly due to variations in CTC identification and treatment strategies [ 29 , 93 , 197 ]. In addition to quantitative analyses, the molecular characteristics of CTCs are also frequently used to assess a patient's treatment response [ 198 ].…”

Section: Clinical Applications In the Management Of Pcmentioning

confidence: 99%

Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation

Wang,

Pan

et al. 2023

Mol Cancer

View full text Add to dashboard Cite

Pancreatic cancer (PC) is one of the most common malignancies. Surgical resection is a potential curative approach for PC, but most patients are unsuitable for operations when at the time of diagnosis. Even with surgery, some patients may still experience tumour metastasis during the operation or shortly after surgery, as precise prognosis evaluation is not always possible. If patients miss the opportunity for surgery and resort to chemotherapy, they may face the challenging issue of chemotherapy resistance. In recent years, liquid biopsy has shown promising prospects in disease diagnosis, treatment monitoring, and prognosis assessment. As a noninvasive detection method, liquid biopsy offers advantages over traditional diagnostic procedures, such as tissue biopsy, in terms of both cost-effectiveness and convenience. The information provided by liquid biopsy helps clinical practitioners understand the molecular mechanisms underlying tumour occurrence and development, enabling the formulation of more precise and personalized treatment decisions for each patient. This review introduces molecular biomarkers and detection methods in liquid biopsy for PC, including circulating tumour cells (CTCs), circulating tumour DNA (ctDNA), noncoding RNAs (ncRNAs), and extracellular vesicles (EVs) or exosomes. Additionally, we summarize the applications of liquid biopsy in the early diagnosis, treatment response, resistance assessment, and prognostic evaluation of PC.

show abstract

“…Powles et al suggested the use of cf DNA with adjuvant atezolizumab to guide the immunotherapy in urothelial carcinoma patients [ 52 ]. Through various studies, clinical evidence of cf DNA as a potential diagnostic marker has been reported for lung cancer [ 53 , 54 ], pancreatic cancer [ 55 , 56 ], melanoma [ 57 ], B-cell lymphoma [ 58 ], and colorectal cancer [ 59 , 60 , 61 ]. Rizzo et al reported the use of cfDNA for the diagnosis of biliary tract cancer [ 62 ].…”

Section: Applications Of Cf Dna and Cf ...mentioning

confidence: 99%

Diagnostic and Therapeutic Potential of Circulating-Free DNA and Cell-Free RNA in Cancer Management

et al. 2022

View full text Add to dashboard Cite

Over time, molecular biology and genomics techniques have been developed to speed up the early diagnosis and clinical management of cancer. These therapies are often most effective when administered to the subset of malignancies harboring the target identified by molecular testing. Important advances in applying molecular testing involve circulating-free DNA (cfDNA)- and cell-free RNA (cfRNA)-based liquid biopsies for the diagnosis, prognosis, prediction, and treatment of cancer. Both cfDNA and cfRNA are sensitive and specific biomarkers for cancer detection, which have been clinically proven through multiple randomized and prospective trials. These help in cancer management based on the noninvasive evaluation of size, quantity, and point mutations, as well as copy number alterations at the tumor site. Moreover, personalized detection of ctDNA helps in adjuvant therapeutics and predicts the chances of recurrence of cancer and resistance to cancer therapy. Despite the controversial diagnostic values of cfDNA and cfRNA, many clinical trials have been completed, and the Food and Drug Administration has approved many multigene assays to detect genetic alterations in the cfDNA of cancer patients. In this review, we underpin the recent advances in the physiological roles of cfDNA and cfRNA, as well as their roles in cancer detection by highlighting recent clinical trials and their roles as prognostic and predictive markers in cancer management.

show abstract

Clinical significance of circulating tumor cells after chemotherapy in unresectable pancreatic ductal adenocarcinoma

Cited by 8 publications

References 42 publications

Identification and gene expression analysis of circulating tumor cells with high expression of KRAS in pancreatic cancer

Identification and gene expression analysis of circulating tumor cells with high expression of KRAS in pancreatic cancer

Liquid biopsy techniques and pancreatic cancer: diagnosis, monitoring, and evaluation

Diagnostic and Therapeutic Potential of Circulating-Free DNA and Cell-Free RNA in Cancer Management

Contact Info

Product

Resources

About